Tibco Spotfire and Integromics Unveil new Genomics Data Aanalysis Solution to Speed Drug Research, Development

TIBCO Software Inc., together with Integromics, a provider of state-of-the-art software solutions for data management and data analysis in genomics, proteomics and drug discovery, today announced Integromics Biomarker Discovery 2.0 for TIBCO Spotfire®, a new solution that sets the standard for advanced methods of data access, normalization, pattern detection, treatment comparison, and functional analysis for scientists analyzing genomic expression data.  This powerful platform plays a pivotal role in leveraging the substantial investment in gene expression technologies that the pharmaceutical and biotechnology industries have made in the last decade.  Gaining new insights into disease biology, mechanism of action, and drug safety will be a key differentiator in early drug discovery.

The scientific and workflow knowledge of INTEGROMICS – combined with the adaptability and ease of use of the TIBCO Spotfire® Enterprise Analytics Platform – provides pharmaceutical, biotechnology, and academic research groups a powerful genomic data analysis environment that quickly finds and categorizes complex patterns.  With interactive analysis and high-impact visualization capabilities, Integromics Biomarker Discovery 2.0 for TIBCO Spotfire® rapidly reveals insights and unexpected relationships in genomics data.  This allows researchers and scientists to examine the expression and annotation dimensions of their data and perform a variety of numerical analyses – all in a single application.  Pharmaceutical companies can also use TIBCO Spotfire® as a flexible analytics platform to combine and analyze new types of data to more quickly pursue hypotheses and research strategies.